011false100true score desc 2gaptrue5mapcontentxmltrue50object_type_i,object_type_i_lookup,coverage_period_mt,geographic_area_mt,geographic_coordinates_mt,author_role_mt,contributor_role_mt,org_id_mt,org_role_mt,supervisor_mt,supervisor_id_mi,supervisor_id_mi_lookup,fields_of_research_mi,fields_of_research_mi_lookup,display_type_i,display_type_i_lookup,seo_code_mi,seo_code_mi_lookup,copyright_i,license_i,license_i_lookup,oa_compliance_t,oa_notes_t,grant_id_t,funding_body_t,description_of_resource_t,software_required_t,project_description_t,keywords_mt,project_name_t,project_id_t,isdatasetof_mt,isdatasetof_mt_lookup,notes_t,date_dt,xsd_display_option_mi,xsd_display_option_mi_lookup,file_downloads_i,created_date_dt,updated_date_dt,research_program_mt,title_t,depositor_i,isderivationof_mt,assigned_user_id_mt,assigned_group_id_mi,assigned_group_id_mi_lookup,isdatacomponentof_mt,isannotationof_mt,author_id_mi,author_id_mi_lookup,alternative_title_mt,pid_t,publisher_t,author_mt,contributor_mt,contributor_id_mi,contributor_id_mi_lookup,refereed_i,series_t,journal_name_t,newspaper_t,conference_name_t,book_title_t,identifier_mt,edition_t,subject_mi,subject_mi_lookup,place_of_publication_t,start_page_t,end_page_t,chapter_number_t,issue_number_t,volume_number_t,conference_dates_t,conference_location_t,patent_number_t,country_of_issue_t,description_t,date_available_dt,language_mt,phonetic_title_t,language_of_title_mt,translated_title_t,phonetic_journal_name_t,translated_journal_name_t,phonetic_book_title_t,translated_book_title_t,phonetic_newspaper_t,file_attachment_name_mt,translated_newspaper_t,phonetic_conference_name_t,translated_conference_name_t,issn_mt,isbn_mt,isi_loc_t,prn_t,output_availability_t,na_explanation_t,sensitivity_explanation_t,file_attachment_content_mt,org_unit_name_t,org_name_t,report_number_t,sequence_i,genre_t,genre_type_t,formatted_title_t,formatted_abstract_t,parent_publication_t,convener_t,ismemberof_mt,ismemberof_mt_lookup,link_mt,link_description_mt,rights_t,views_i,scopus_id_t,thomson_citation_count_i,gs_citation_count_i,gs_cited_by_link_t,scopus_citation_count_i,status_i,status_i_lookup,first_author_in_document_derived_t,first_author_in_fez_derived_t,ands_collection_type_t,start_date_dt,end_date_dt,access_conditions_t,extent_t,contact_details_email_mt,contact_details_physical_mt,loc_subject_heading_mt,depositor_affiliation_i,surrounding_features_mt,condition_mt,style_mt,period_mt,category_mt,subcategory_mt,structural_systems_mt,adt_id_t,subtype_t,language_of_parent_title_t,proceedings_title_t,file_description_mt,herdc_code_i,herdc_code_i_lookup,herdc_status_i,herdc_status_i_lookup,institutional_status_i,institutional_status_i_lookup,herdc_notes_t,follow_up_flags_i,follow_up_flags_i_lookup,follow_up_flags_imu_i,follow_up_flags_imu_i_lookup,scopus_doc_type_t,scopus_doc_type_t_lookup,wok_doc_type_t,wok_doc_type_t_lookup,conference_id_i,total_chapters_t,publisher_id_i,translated_proceedings_title_t,native_script_title_t,roman_script_title_t,native_script_book_title_t,roman_script_book_title_t,native_script_journal_name_t,roman_script_journal_name_t,native_script_conference_name_t,roman_script_conference_name_t,total_pages_t,native_script_proceedings_title_t,roman_script_proceedings_title_t,language_of_book_title_mt,language_of_journal_name_mt,language_of_proceedings_title_mt,doi_t,author_count_t,collection_year_dt,location_mt,building_materials_mt,architectural_features_mt,interior_features_mt,sherpa_colour_t,ain_detail_t,rj_2010_rank_t,rj_2010_title_t,rj_2012_rank_t,rj_2012_title_t,rc_2010_rank_t,rc_2010_title_t,herdc_code_description_t,score,citation_t1true60 (test AND author_mt:(David Teira) AND status_i:(2)) 6display_type_idisplay_type_i_lookup_exactkeywords_mftdate_year_tauthor_id_miauthor_id_mi_lookup_exactauthor_mftjournal_name_t_ftsubject_misubject_mi_lookup_exactgenre_type_t_ftismemberof_mftismemberof_mt_lookup_exactsubtype_t_ftscopus_doc_type_t_ftscopus_doc_type_t_lookup_exact(_authlister_t:(1)) AND (status_i:(2)) 34452016-01-01T00:00:00Z5252016-04-03T09:54:07Z2016-04-03T09:54:07ZTesting oncological treatments in the era of personalized medicine33bibliuned:5010900Book5032<a class="citation_author_name" title="Navegar por nombre de Autor de David Teira" href="/fez/list/author/David Teira/">David Teira</a>, <i><a class="citation_title" title="Click para ver : Testing oncological treatments in the era of personalized medicine" href="/fez/view/bibliuned:501090">Testing oncological treatments in the era of personalized medicine</a></i>. , <span class="citation_date">2016</span> ()RecordLibrosPublishedsmall trialsphase II trialscancertargeted treatments33David Teira1bibliuned:501090TeiraTestingOncologicalTreatments.pdfpresmd_TeiraTestingOncologicalTreatments.xmlbibliuned:68Departamento Lógica, Historia, Filosofía de la Ciencia (UNED). Capítulos de librosDavid Teira5.287225734232020-01-30T00:00:00Z4412020-01-30T19:07:37Z2020-01-30T19:07:37ZA Defence of Pharmaceutical Paternalism67255bibliuned:501123Pharmaceutical paternalism is the normative stance upheld by pharmaceutical regulatory agencies like the US Food and Drug Administration. These agencies prevent patients from accessing treatments declared safe and ineffective for the patient’s good without their consent. Libertarian critics of the FDA have shown a number of significant flaws in regulatory paternalism. Against these objections, I will argue that, in order to make an informed decision about treatments, a libertarian patient should request full disclosure of the uncertainty about an experimental treatment. But pharmaceutical markets, on their own, are not a reliable source of information about such uncertainty. And companies have the power to capture any independent expert who may assess it. Therefore, the libertarian is better off deferring on an independent regulatory body the assessment of the pharmaceutical risks, constraining access to treatments until tested.05022<a class="citation_author_name" title="Navegar por nombre de Autor de David Teira" href="/fez/list/author/David Teira/">David Teira</a> . (<span class="citation_date">2020</span>) <a class="citation_title" title="Click para ver : A Defence of Pharmaceutical Paternalism" href="/fez/view/bibliuned:501123">A Defence of Pharmaceutical Paternalism</a>. RecordArtículo de revistaPublishedFilosofía67255David Teira1Journal of Applied Philosophybibliuned:501123TeiraPharmaceuticalPaternalism.pdfpresmd_TeiraPharmaceuticalPaternalism.xmlbibliuned:81Departamento Lógica, Historia, Filosofía de la Ciencia (UNED). ArtículosDavid TeiraAcceso abiertohttps://doi.org/10.1111/japp.124134.95211934232019-07-01T00:00:00Z3272019-07-04T00:25:10Z2019-07-04T00:25:10ZPlacebo trials without mechanisms: How far can they go?67255bibliuned:501121In this paper, I suggest that placebo effects, as we know them today, should be understood as experimental phenomena, low-level regularities whose causal structure is grasped through particular experimental designs with little theoretical guidance. Focusing on placebo interventions with needles for pain reduction -one of the few placebo regularities that seems to arise in meta-analytical studies- I discuss the extent to which it is possible to decompose the different factors at play through more fine-grained randomized clinical trials. My sceptical argument is twofold. On the one hand, I argue that experiments alone are not enough to standardize interventions, and that it is necessary to include theories. On the other hand, I argue that the social interactions that seem to be part of placebo effects are difficult, if not impossible, to blind. Therefore, the measurement biases arising from the participants’ reactivity to the experimental setup cannot be controlled for. Further decomposition of placebo effects requires a theoretical account of the existing experimental regularities that may guide further tests.04802<a class="citation_author_name" title="Navegar por nombre de Autor de David Teira" href="/fez/list/author/David Teira/">David Teira</a> . (<span class="citation_date">2019</span>) <a class="citation_title" title="Click para ver : Placebo trials without mechanisms: How far can they go?" href="/fez/view/bibliuned:501121">Placebo trials without mechanisms: How far can they go?</a>. RecordArtículo de revistaPublishedFilosofía67255David Teira1Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciencesbibliuned:501121TeiraPlacebo.pdfpresmd_TeiraPlacebo.xmlbibliuned:81Departamento Lógica, Historia, Filosofía de la Ciencia (UNED). ArtículosDavid TeiraAcceso abiertohttps://doi.org/10.1016/j.shpsc.2019.1011774.92878434232019-01-01T00:00:00Z3242019-06-06T02:23:54Z2019-06-06T02:23:54ZRules versus standards: what are the costs of epistemic norms in drug regulation?67255bibliuned:501116Over the last decade, philosophers of science have extensively criticized the epistemic superiority of Randomized Controlled Trials (RCTs) for testing safety and effectiveness of new drugs, defending instead various forms of evidential pluralism. We argue that scientific methods in regulatory decision making cannot be assessed in epistemic terms only: there are costs involved. Drawing on the legal distinction between rules and standards, we show that drug regulation based on evidential pluralism has much higher costs than our current RCT-based system. We analyze these costs and advocate for evaluating any scheme for drug regulatory tests in terms of concrete empirical benchmarks, like the error rates of regulatory decisions.05272<a class="citation_author_name" title="Navegar por nombre de Autor de Andreoletti, Mattia" href="/fez/list/author/Andreoletti, Mattia/">Andreoletti, Mattia</a> y <a class="citation_author_name" title="Navegar por nombre de Autor de Teira, David" href="/fez/list/author/Teira, David/">Teira, David</a> . (<span class="citation_date">2019</span>) <a class="citation_title" title="Click para ver : Rules versus standards: what are the costs of epistemic norms in drug regulation?" href="/fez/view/bibliuned:501116">Rules versus standards: what are the costs of epistemic norms in drug regulation?</a>. RecordArtículo de revistaPublishedFilosofía67255Andreoletti, MattiaTeira, David1Science, Technology and Human Valuesbibliuned:501116AndreolettiTeira.pdfpresmd_AndreolettiTeira.xmlbibliuned:81Departamento Lógica, Historia, Filosofía de la Ciencia (UNED). ArtículosAndreolettiAcceso abiertohttps://doi.org/10.1177/01622439198280704.06245934232013-06-04T00:00:00Z14062013-06-04T21:17:28Z2015-10-31T04:36:09ZOn the impartiality of early British clinical trialsbibliuned:500681Did the impartiality of clinical trials play any role in their acceptance as regulatory standards for the safety and efficacy of drugs? According to the standard account of early British trials in the 1930s and 1940s, their impartiality was just rhetorica06032<a class="citation_author_name" title="Navegar por nombre de Autor de Teira Serrano, David" href="/fez/list/author/Teira Serrano, David/">Teira Serrano, David</a> . (<span class="citation_date">2013</span>) <a class="citation_title" title="Click para ver : On the impartiality of early British clinical trials" href="/fez/view/bibliuned:500681">On the impartiality of early British clinical trials</a>. RecordArtículo de revistaPublishedclinical trials, Streptomycin, fair test, impartialityTeira Serrano, Davidbibliuned:500681ImpartialityBritishTrialsBlind.pdfbibliuned:81bibliuned:Setopenairebibliuned:SetarticuloDepartamento Lógica, Historia, Filosofía de la Ciencia (UNED). ArtículosSet de openaireSet de artículohttp://creativecommons.org/licenses/by-nc-nd/4.0Licencia Creative CommonsTeira SerranoAcceso abierto4.01813434232020-03-01T00:00:00Z6882021-02-26T18:15:35Z2021-02-26T18:15:35ZWhy Experimental Balance is Still a Reason to Randomize67255bibliuned:501130Experimental balance is usually understood as the control for the value of the conditions, other than the one under study, which are liable to affect the result of a test. We will discuss three different approaches to balance. ‘Millean balance’ requires to identify and equalize ex ante the value of these conditions in order to conduct solid causal inferences. ‘Fisherian balance’ measures ex post the influence of uncontrolled conditions through the analysis of variance. In ‘efficiency balance’ the value of the antecedent conditions is decided ex ante according to the efficiency they yield in the estimation of the treatment outcome. Against some old arguments by John Worrall, we will show that in both Fisherian and efficiency balance there are good reasons to randomize the allocation of treatments, in particular when there is no agreement among experimenters as to the antecedent conditions to be controlled for.02392<a class="citation_author_name" title="Navegar por nombre de Autor de Marco Martinez" href="/fez/list/author/Marco Martinez/">Marco Martinez</a> y <a class="citation_author_name" title="Navegar por nombre de Autor de David Teira" href="/fez/list/author/David Teira/">David Teira</a> . (<span class="citation_date">2020</span>) <a class="citation_title" title="Click para ver : Why Experimental Balance is Still a Reason to Randomize" href="/fez/view/bibliuned:501130">Why Experimental Balance is Still a Reason to Randomize</a>. RecordArtículo de revistaPublishedFilosofía67255Marco MartinezDavid Teira1British Journal for the Philosophy of Sciencebibliuned:501130MartinezTeiraBJPSRandomizationBalance.pdfpresmd_MartinezTeiraBJPSRandomizationBalance.xmlbibliuned:81Departamento Lógica, Historia, Filosofía de la Ciencia (UNED). ArtículosMarco MartinezAcceso abierto3.994799434452012-04-11T00:00:00Z13462012-04-11T21:26:21Z2015-10-31T04:47:00ZThe ethics of statistical testingbibliuned:5005240Book6182<a class="citation_author_name" title="Navegar por nombre de Autor de Sprenger, Jan" href="/fez/list/author/Sprenger, Jan/">Sprenger, Jan</a> y <a class="citation_author_name" title="Navegar por nombre de Autor de Teira Serrano, David" href="/fez/list/author/Teira Serrano, David/">Teira Serrano, David</a>, <i><a class="citation_title" title="Click para ver : The ethics of statistical testing" href="/fez/view/bibliuned:500524">The ethics of statistical testing</a></i>. , <span class="citation_date">2012</span> ()RecordLibrosPublishedsignicance testingconsequentialismexpected utility theoryfrequentismBayesianismp-valuesSprenger, JanTeira Serrano, Davidbibliuned:500524engSprengerTeiraIndexed.pdfbibliuned:68bibliuned:SetopenaireDepartamento Lógica, Historia, Filosofía de la Ciencia (UNED). Capítulos de librosSet de openairehttp://creativecommons.org/licenses/by-nc-nd/4.0Licencia Creative CommonsSprenger3.8311625525242242522522